Abstract:Past research indicated that methylseleninic acid (MSA) is an excellent tool for investigating the cancer chemopreventive action of selenium in vitro. The present study was designed to examine the cellular and molecular effects of MSA in the MCF10AT1 and MCF10AT3B premalignant human breast cells. After exposure to MSA, both cell lines exhibited a dose- and time-dependent growth-inhibitory response as determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay. Further characterization of cellular and molecular changes was carried out only with the MCF10AT1 cells. Flow cytometry analysis showed that MSA blocked cell cycle progression at the G(0)-G(1) phase. Induction of apoptosis was also observed with the use of either the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) or the annexin V binding method. cDNA microarray analyses with cell cycle- and apoptosis-targeted arrays were then applied to profile the gene expression changes mediating these two cellular events. The analyses were conducted at 6 and 12 h of MSA treatment using synchronized cells. The expression signals of 30 genes were found to be significantly altered by MSA. These genes fall into three categories: cell cycle checkpoint controllers (e.g., cyclins, cdcs, cdks, E2F family proteins, and serine/threonine kinases), apoptosis regulatory genes (e.g., Apo-3, c-jun, and cdk5/cyclin D1), and signaling molecules [e.g., mitogen-activated protein (MAP)/extracellular signal-regulated protein kinase (ERK) and phosphatidylinositol 3'-kinase (PI3k) cascade genes]. The expression changes of 15 genes were selected for verification by Western or semiquantitative reverse transcription-PCR analyses. An agreement rate of 60% (9 of 15) was obtained from these confirmation experiments. On the basis of the above findings, tentative signaling pathways mediating the outcome of selenium-induced cell cycle arrest and apoptosis are proposed. The present study thus demonstrated the feasibility of applying cDNA microarray technology in delineating the mechanisms of the action of selenium and in pinpointing molecular targets as potential biomarkers for evaluating the efficacy of selenium intervention.

Microwave-Assisted Syntheses of Benzimidazole-Containing Selenadiazole Derivatives That Induce Cell-Cycle Arrest and Apoptosis in Human Breast Cancer Cells by Activation of the ROS/AKT Pathway.

Synthesis of Selenazolopyridine Derivatives with Capability to Induce Apoptosis in Human Breast Carcinoma MCF-7 Cells Through Scavenge of Intracellular ROS.

Mitochondria-mediated apoptosis in human breast carcinoma MCF-7 cells induced by a novel selenadiazole derivative.

Camphor-Based Thiosemicarbazone Analogues Induced G2 Cell Cycle Arrest And Apoptosis Via Reactive Oxygen Species (Ros)-Mediated Mitochondrial Pathway In Human Breast Cancer Cells

Synthesis and in Vitro Anticancer Activity of 6,7-Methylenedioxy (or 5-Hydroxy-6-methoxy)-2-(substituted Selenophenyl)Quinolin-4-One Analogs

Design and Synthesis of 2-(5-phenylindol-3-yl)benzimidazole Derivatives with Antiproliferative Effects Towards Triple-Negative Breast Cancer Cells by Activation of ROS-Mediated Mitochondria Dysfunction

Sensitization of Cancer Cells to Radiation by Selenadiazole Derivatives by Regulation of ROS-mediated DNA Damage and ERK and AKT Pathways.

Highly Stable Selenadiazole Derivatives Induce Bladder Cancer Cell Apoptosis and Inhibit Cell Migration and Invasion Through the Activation of ROS-mediated Signaling Pathways

Caspase- and P53-Dependent Apoptosis in Breast Carcinoma Cells Induced by a Synthetic Selenadiazole Derivative

A Novel Selenadiazole Derivative Induces Apoptosis in Human Glioma Cells by Dephosphorylation of AKT

New Organoselenium (NSAIDs-Selenourea and Isoselenocyanate) Derivatives as Potential Antiproliferative Agents: Synthesis, Biological Evaluation and in Silico Calculations

Identification of Molecular Targets Associated with Selenium-Induced Growth Inhibition in Human Breast Cells Using Cdna Microarrays.

Selenadiazole Derivatives As Theranostic Agents for Simultaneous Cancer Chemo-/Radiotherapy by Targeting Thioredoxin Reductase

Selenocystine Induces Caspase-Independent Apoptosis in MCF-7 Human Breast Carcinoma Cells with Involvement of P53 Phosphorylation and Reactive Oxygen Species Generation.

Selenadiazole Derivatives Inhibit Angiogenesis-Mediated Human Breast Tumor Growth by Suppressing the VEGFR2-Mediated ERK and AKT Signaling Pathways.

Selenocystine Induces S-phase Arrest and Apoptosis in Human Breast Adenocarcinoma MCF-7 Cells by Modulating ERK and Akt Phosphorylation.

Rational Design of Cancer-Targeted Benzoselenadiazole by Rgd Peptide Functionalization for Cancer Theranostics

Synthesis and Biological Evaluation of Organoselenium (Nsaids-Secn and SeCF3) Derivatives As Potential Anticancer Agents.

An Integrin-Targeting Nanosystem As a Carrier of the Selenadiazole Derivative to Induce ROS-mediated Apoptosis in Bladder Cancer Cells, from Rational Design to Action Mechanisms

Synthesis and Biological Activity of Novel Organoselenium Derivatives Targeting Multiple Kinases and Capable of Inhibiting Cancer Progression to Metastases

Fused isoselenazolium salts suppress breast cancer cell growth by dramatic increase in pyruvate-dependent mitochondrial ROS production